10-Q quarterly report · filed Nov 4, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 10-Q Quarterly Report

Short answer

Arcutis Biotherapeutics, Inc. (ARQT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $144M (up 45.1% year over year) with net income of $9M.

Q3 2026 key financials · XBRL

Revenue
$144M
+45.1% YoY · +10.8% QoQ
Net income
$9M
+18.8% YoY · −41.4% QoQ
Operating margin
6.6%
EPS (diluted)
$0.06
+0.0% YoY · −50.0% QoQ

Source: XBRL data from the Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 10-Q on SEC EDGAR. USD.

Arcutis Biotherapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly product revenue $143.9M, up $44.7M YoY from $99.2M
  • Best performer: ZORYVE foam revenue $75.1M vs $49.8M YoY, up $25.4M
  • ZORYVE cream 0.05% revenue $3.7M, launched October 2025
  • Operating cash flow $33.8M in nine months vs $(31.8)M YoY, cash and securities $259.8M
  • Outlook: R&D and SG&A expected to increase, primarily for ARQ-234 and ZORYVE commercialization

Risk Factors

  • No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
  • Carried-forward risks include potential risks and uncertainties described in the 2025 Annual Report

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Arcutis Biotherapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.